BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27327964)

  • 1. Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.
    Wagenlehner FM; Alidjanov JF
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):959-66. PubMed ID: 27327964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
    Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
    Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
    Sucher AJ; Chahine EB; Cogan P; Fete M
    Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
    Cho JC; Fiorenza MA; Estrada SJ
    Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H; Körber-Irrgang B; Kresken M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials.
    Popejoy MW; Paterson DL; Cloutier D; Huntington JA; Miller B; Bliss CA; Steenbergen JN; Hershberger E; Umeh O; Kaye KS
    J Antimicrob Chemother; 2017 Jan; 72(1):268-272. PubMed ID: 27707990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
    Eckmann C; Solomkin J
    Expert Opin Pharmacother; 2015 Feb; 16(2):271-80. PubMed ID: 25529765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
    Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
    Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
    Scott LJ
    Drugs; 2016 Feb; 76(2):231-42. PubMed ID: 26746849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
    Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
    Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial.
    Huntington JA; Sakoulas G; Umeh O; Cloutier DJ; Steenbergen JN; Bliss C; Goldstein EJ
    J Antimicrob Chemother; 2016 Jul; 71(7):2014-21. PubMed ID: 26994090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.
    Bassetti M; Righi E
    Future Microbiol; 2015; 10(2):151-60. PubMed ID: 25689527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.
    Armstrong ES; Mikulca JA; Cloutier DJ; Bliss CA; Steenbergen JN
    BMC Infect Dis; 2016 Nov; 16(1):710. PubMed ID: 27887579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftolozane-tazobactam: A new-generation cephalosporin.
    Cluck D; Lewis P; Stayer B; Spivey J; Moorman J
    Am J Health Syst Pharm; 2015 Dec; 72(24):2135-46. PubMed ID: 26637512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
    Tato M; García-Castillo M; Bofarull AM; Cantón R;
    Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam.
    Popejoy MW; Long J; Huntington JA
    BMC Infect Dis; 2017 May; 17(1):316. PubMed ID: 28464828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
    Vickery SB; McClain D; Wargo KA
    Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antimicrobial activity of ceftolozane/tazobactam against Enterobacteriaceae and Pseudomonas aeruginosa in the Czech Republic in 2016].
    Žemličková H; Jakubů V; Fridrichová M
    Klin Mikrobiol Infekc Lek; 2017 Dec; 23(4):132-135. PubMed ID: 29378381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.